brain tumor

  •  

    How an Expert Would Treat His Own Glioblastoma

    With: Al Musella, DPM

    Two years ago, our Curious Dr. George asked Al Musella, DPM, what he would do if he were diagnosed with glioblastoma multiforme (GBM). Here, he revisits that question. Dr. Musella is President of the Musella Foundation For Brain Tumor Research… Read more »

  •  

    Facilitating Access to Treatment for Children with Brain Cancer

    With: Leslie Jared, RN, MSN

    A Q&A with Leslie Jared, RN, MSN, Nurse Navigator at Cancer Commons. Email: leslie.jared@cancercommons.org Q: A midline glioma is a type of brain tumor that is particularly dangerous because of its nature and its location in the brain. It often… Read more »

  •   George Lundberg, MD

    Article from Michigan Health Lab curated by Editor in Chief George Lundberg, MD, who notes: 

    Children with serious brain tumors need access to as many clinical trials as possible. This new consortium will encourage that.

    Go to full article published by Michigan Health Lab.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    Securing participation in clinical trials is a continuing and serious problem of clinical research for many cancers. This paper describes an effort to improve participation for brain cancer clinical trials.

    Go to full article published by Neuro-Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Announcement from the College of American Pathologists curated by Editor in Chief George Lundberg, MD, who notes: 

    What forms of testing should be done for diffuse gliomas? In this announcement, a global panel invites comments about proposals.

    Go to full announcement published by the College of American Pathologists.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •  

    Fixed and Variable Factors that Impact a Brain Tumor Patient’s Prognosis

    George Lundberg, MD

    A Q&A with Burt Nabors, MD, Professor and Director of the Division of Neuro-oncology at the University of Alabama, Birmingham, and a member of the Cancer Commons Brain Tumor Advisory Board; bnabors@uabmc.edu Q: Primary brain gliomas can be devastating, often… Read more »

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD:

    Receiving a brain tumor diagnosis can be shocking for patients and their families. The Musella Foundation’s free “Brain Tumor Guide for the Newly Diagnosed” provides up-to-date guidance for people in this difficult position.

    .

  •  

    Case Report in the Journal of Neurosurgery Highlights Potential of ONC201 in H3 K27M-mutant DIPG

    Last fall, we announced our collaboration with Musella Foundation, xCures, The Cure Starts Now Foundation, Michael Mosier Defeat DIPG Foundation, and Oncoceutics to help patients access ONC201, a new, experimental treatment for a type of brain tumor known as diffuse intrinsic pontine glioma (DIPG), as well as other gliomas… Read more »

  •  

    Promising Developments for Brain Tumor Drug ONC201

    In September, we announced our collaboration with Musella Foundation, xCures, and Oncoceutics to help patients access ONC201, a potential new treatment for a type of brain tumor known as diffuse intrinsic pontine glioma (DIPG), as well as other gliomas with a genetic mutation known as H3… Read more »

  •   Emma Shtivelman, PhD

    Excerpt:

    “Instructing the immune system to recognize and kill tumours, an approach termed cancer immunotherapy, has transformed the clinical treatment of certain types of malignancy. Prominent among these therapies are immune-checkpoint inhibitors, which block the action of proteins that dampen immune-cell responses against tumours. For example, antibodies can be used to interfere with the inhibitory protein PD-1, which is present on T cells, a type of immune cell that attacks tumours. Immune-checkpoint inhibitors have been most successfully used to treat cancers, such as melanomas, that are well infiltrated by T cells and have a large number of genetic mutationsA subset of these mutations might generate neoantigens — altered protein sequences that are uniquely produced in cancer cells and are recognized as foreign by the immune system.”

    Go to full article published by Nature on Dec 19, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.